A detailed history of Ensign Peak Advisors, Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 177,471 shares of VRTX stock, worth $72.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
177,471
Previous 183,704 3.39%
Holding current value
$72.4 Million
Previous $86.1 Million 4.14%
% of portfolio
0.15%
Previous 0.16%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $2.87 Million - $3.15 Million
-6,233 Reduced 3.39%
177,471 $82.5 Million
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $16 Million - $19.8 Million
-40,789 Reduced 18.17%
183,704 $86.1 Million
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $178 Million - $195 Million
-436,034 Reduced 66.01%
224,493 $93.8 Million
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $32.6 Million - $39 Million
-94,975 Reduced 12.57%
660,527 $269 Million
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $4.05 Million - $4.35 Million
-11,990 Reduced 1.56%
755,502 $263 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $5.7 Million - $6.38 Million
18,132 Added 2.42%
767,492 $270 Million
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $91.2 Million - $104 Million
321,980 Added 75.34%
749,360 $236 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $9.06 Million - $10.2 Million
31,689 Added 8.01%
427,380 $123 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $8.44 Million - $9.41 Million
30,810 Added 8.44%
395,691 $115 Million
Q2 2022

Aug 12, 2022

BUY
$234.96 - $292.55 $7.42 Million - $9.24 Million
31,572 Added 9.47%
364,881 $103 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $8.33 Million - $9.82 Million
37,631 Added 12.73%
333,309 $87 Million
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $26.8 Million - $33.9 Million
-151,534 Reduced 33.88%
295,678 $64.9 Million
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $28.7 Million - $32.1 Million
-158,321 Reduced 26.15%
447,212 $81.1 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $11.2 Million - $13.2 Million
59,685 Added 10.93%
605,533 $122 Million
Q1 2021

May 12, 2021

BUY
$207.02 - $241.31 $852,094 - $993,231
4,116 Added 0.76%
545,848 $117 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $8.48 Million - $11.3 Million
40,970 Added 8.18%
541,732 $128 Million
Q3 2020

Nov 12, 2020

SELL
$255.65 - $303.1 $31.4 Million - $37.2 Million
-122,808 Reduced 19.69%
500,762 $136 Million
Q2 2020

Aug 12, 2020

SELL
$225.48 - $295.8 $39.7 Million - $52 Million
-175,878 Reduced 22.0%
623,570 $181 Million
Q1 2020

May 11, 2020

SELL
$199.77 - $247.81 $2.13 Million - $2.64 Million
-10,669 Reduced 1.32%
799,448 $190 Million
Q4 2019

Feb 14, 2020

BUY
$166.71 - $223.91 $135 Million - $181 Million
810,117 New
810,117 $177 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.